A promising therapeutic target is the interleukin-3 (IL-3) receptor subunit alpha (IL-3Rα/CD123), which is strongly expressed on blasts and LSPCs in AML and HR-MDS but is either absent or weakly expressed on healthy hematopoietic stem cells8–10. Here, IL3RA is linked to myelodysplastic syndrome.